# ADMA — AI stock forecast & analysis

> AI-generated analysis by K3vl4r — 2026-07-02. Informational only, not financial advice.

**Recommendation:** HOLD

**Scores (0–100):** Overall 5.5 · Fundamentals 7.2 · Technicals 4 · Growth 6.5 · Risk 7.5

## Summary

ADMA Biologics trades at $8.68 with strong operational fundamentals (43% ROE, 32% net margin, $55M Q1 FCF) but is under a heavy overhang from a June 2026 securities lawsuit alleging revenue inflation, which has driven a -52% YTD decline from the $20.46 52-week high. Forward P/E of 8.5 and PEG of 0.29 look cheap on paper, but legal risk and a pending Aug 5 earnings print make this a HOLD with tactical accumulation zones near $7.20-$8.00 support.

## Price targets (12-month horizon)

- Bear: $6.50
- Base: $10.50
- Bull: $14.00

## News context

The dominant signal is the June 2026 federal securities lawsuit alleging revenue inflation — this is the single most important overhang and explains the -52% YTD drawdown. Offsetting this is Raymond James resuming coverage (June 10) and a 121% upside call implied by the $17.75 consensus target, indicating sell-side still sees fundamental value once legal fog clears. Recent daily action articles are noise (small moves, standard Zacks reports). The MarketBeat catalyst piece flags ADMA as one of three biotechs with major upcoming catalysts, which aligns with the Aug 5 earnings print being the next binary event.

## About
- Methodology: https://app.k3vl4r.com/methodology
- Full report: https://app.k3vl4r.com/r/adma-ai-stock-forecast-64995f26b2389067f4265b4f35e06cf1
- AI-generated; model outputs can be wrong. Not financial advice.